CJC-1295 (no DAC)
The gold-standard GHRH analogue — amplifies pituitary GH pulses physiologically. Best combined with Ipamorelin.
Research facts
| Half-life | ~30 minutes |
|---|---|
| Route | SubQ |
| Typical dose | 100–200 mcg |
| Frequency | 2× daily (with Ipamorelin) |
| Solvent | Bacteriostatic water |
| pH | 5.0–7.0 |
| Stability | 30 days at +4°C |
Mechanism of action
CJC-1295 (no DAC) is a truncated analogue of GHRH (Growth Hormone Releasing Hormone), specifically the first 29 amino acids modified at positions 2, 8, 15, and 27 for improved protease resistance. It binds to GHRH receptors in the anterior pituitary to amplify the amplitude of existing GH pulses without altering pulse frequency — preserving physiological pulsatility.
The short half-life (~30 min) produces a more physiological GH release pattern than the long-acting DAC version. When injected simultaneously with a GHRP (Ipamorelin), it produces synergistic GH release 4–6× greater than either alone: GHRH amplifies the pulse while GHRP triggers it. The combination allows both peptides to be drawn in the same syringe, simplifying protocol compliance.
CJC-1295 no-DAC was removed from the FDA Category 2 restricted list in April 2026.
Documented effects (research-model)
- Physiological GH pulse amplification without continuous elevation
- Body composition improvement via IGF-1 elevation
- Sleep quality and deep sleep architecture enhancement
- Recovery acceleration through GH/IGF-1 axis
- Anti-ageing endocrine optimisation
- Bone density support
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Standard | 100 mcg + Ipamorelin 200 mcg | Same syringe, 2× daily | 12 weeks on / 4 weeks off | 2mg / 2mL BAC water |
| Advanced | 200 mcg + Ipamorelin 300 mcg | AM fasted + bedtime | 12 weeks | 2mg / 1mL BAC water |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- Ipamorelin HIGH
The definitive GH stack — GHRH (amplitude) + GHRP (trigger) = 4–6× GH output. Draw in same syringe. - IGF-1 LR3 MODERATE
CJC-1295 raises endogenous GH→IGF-1; IGF-1 LR3 adds direct IGF-1R activation. - Tesamorelin LOW
Both are GHRH analogues — generally not combined due to redundant mechanism.
Myths & misconceptions
Evidence gaps
- No human RCTs for athletic performance or body composition. Studies use the similar MOD GRF 1-29 framework.
- Long-term pituitary receptor downregulation with sustained use not characterised in humans.
- Optimal no-DAC dose in combination protocols not established by prospective trial.
Safety notes
Removed from FDA Category 2 April 2026. Monitor IGF-1 — keep within age-appropriate reference range. Fasting 2h before and 30 min after injection maximises GH pulse.
Biomarkers to monitor
Primary-source citations
- PMID 16352683 — Stimulation of growth hormone secretion by a GHRH-mimetic (J Clin Endocrinol Metab. 2006)
Frequently asked
What is CJC-1295 (no DAC)?
CJC-1295 (no DAC) (Modified GRF 1-29 — Short-Acting GHRH Analogue) is a research compound classified in our library as Tier B — Some human data + strong preclinical evidence.. The gold-standard GHRH analogue — amplifies pituitary GH pulses physiologically. Best combined with Ipamorelin.
What is the evidence tier for CJC-1295 (no DAC)?
We classify CJC-1295 (no DAC) as Tier B: Some human data + strong preclinical evidence. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of CJC-1295 (no DAC)?
For CJC-1295 (no DAC), typical research dose is 100–200 mcg, route is SubQ, half-life is ~30 minutes. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
What does CJC-1295 (no DAC) stack well with?
CJC-1295 (no DAC) stacks well with Ipamorelin. The definitive GH stack — GHRH (amplitude) + GHRP (trigger) = 4–6× GH output. Draw in same syringe.
Is CJC-1295 (no DAC) safe?
Removed from FDA Category 2 April 2026. Monitor IGF-1 — keep within age-appropriate reference range. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.